To explain parts of this variability and identify mechanistically plausible predictors for long-term response, we developed a population quantitative systems pharmacology (QSP) model, characterizing the human kinetics of four CAR-T cell phenotypes and CD19+ metabolic tumor volume and the dynamics of their interactions. Here, CD19 is linked to neoplasm.